Enregistrement :
4
de
16
(2010-06-18
à
2011-02-16)
Politique ou Programme
Health Canada regarding the need for appropriate, dedicated resources for the Therapeutic Products Directorate to meet performance targets for the review of generic drug submissions.
Health Canada, Industry Canada, and International Trade Canada regarding effective measures to combat counterfeit drugs in Canada and around the world.
Science and Technology Strategy regarding the need for a balanced Intellectual Property (IP) regime and the important role competition plays in encouraging innovation.
The development and implementation of an approval pathway for Subsequent Entry Biologics (SEBs).
Proposition législative, Projet de loi ou résolution
Industry Canada regarding export provisions of the Patent Act.
Industry Canada with respect to the Patent Act as it pertains to pharmaceuticals.
Modernization of the Food and Drug Act (formerly Bill C-51) with respect to the development and implementation of a Progressive Licensing Framework for pharmaceuticals.
Règlement
Amendments to the Patented Medicines (Notice of Compliance) Regulations with regard to section 8 of the regulations, the inclusion of a mechanism that would prevent a brand company from suing a generic company twice on the same patent and an administrative change to explicitly allow a generic company to amend a Notice of Allegation.